The burden of caring for adults with depression and suicidal ideation in five large European countries: analysis from the 2020 National Health and Wellness Survey

por Jaffe, D. H., Balkaran, B. L., Yue, L., Mulhern-Haughey, S., Anjo, J.
Publicado 2021

Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression:...

por Oliveira-Maia, Albino J., Rive, Benoit, Morrens, Joachim, Godinov, Yordan, Cabrieto, Jedelyn, Perualila, Nolen, Mulhern-Haughey, Siobhán
Publicado 2023

ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in...

por Oliveira-Maia, Albino J., Morrens, Joachim, Rive, Benoit, Godinov, Yordan, Cabrieto, Jedelyn, Perualila, Nolen, Barbreau, Sebastien, Mulhern-Haughey, Siobhán
Publicado 2023

Clinical characteristics of treatment-resistant depression in adults in Hungary: Real-world evidence from a 7-year-long retrospective data analysis

por Döme, Péter, Kunovszki, Péter, Takács, Péter, Fehér, László, Balázs, Tamás, Dede, Károly, Mulhern-Haughey, Siobhán, Barbreau, Sébastien, Rihmer, Zoltán
Publicado 2021

Esketamine Nasal Spray Improves Rate and Time to Remission Versus Quetiapine Extended Release in Subgroups of Patients With Treatment Resistant Depression and Two or Three Plus Pri...

por Young, A.H., Cubała, W.J., Nielsen, R.E., Popova, A., Ito, T., Mulhern-Haughey, S., Pirotte, N., Rive, B., Thilakarathne, P., Usankova, I., Godinov, Y.
Publicado 2023

Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depressio...

por Reif, A., Anıl Yağcıoğlu, A. E., Luts, A., Messer, T., Nielsen, R., Buyze, J., Ito, T., Kambarov, Y., Mulhern Haughey, S., Rive, B., Usankova, I., von Holt, C., Godinov, Y.
Publicado 2023